Drug Profile
Lamivudine/nevirapine/zidovudine - Mylan Laboratories
Alternative Names: Lamivudine/zidovudine/nevirapine - Mylan Laboratories; Nevirapine/lamivudine/zidovudine - Mylan Laboratories; Nevirapine/zidovudine/lamivudine - Mylan Laboratories; Zidovudine/lamivudine/nevirapine - Mylan Laboratories; Zidovudine/nevirapine/lamivudine - Mylan LaboratoriesLatest Information Update: 26 Nov 2018
Price :
$50
*
At a glance
- Originator Mylan Laboratories Limited
- Class 3-ring heterocyclic compounds; Antiretrovirals; Azepines; Azides; Cyclopropanes; Deoxyribonucleosides; Dideoxynucleosides; Nucleosides; Pyridines; Pyrimidine nucleosides; Small molecules
- Mechanism of Action Non-nucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered HIV-1 infections
Most Recent Events
- 26 Nov 2018 Lamivudine/nevirapine/zidovudine is not yet available in USA for HIV-1 infections (Mylan website, November 2018)